RET NSCLC Test sale cost 1800 AED
BRAF Mutation Analysis V600E Test sale cost 1800 AED BRAF Mutation Analysis V600E Test Cost 2,400 د.إ Original price was: 2,400 د.إ.1,800 د.إCurrent price is: 1,800 د.إ.
WT-1 Mutation Detection Test sale cost 2040 AED WT-1 Mutation Detection Test Cost 2,400 د.إ Original price was: 2,400 د.إ.2,040 د.إCurrent price is: 2,040 د.إ.
Sale!

RET NSCLC Test Cost

Original price was: 2,400 د.إ.Current price is: 1,800 د.إ.

-25%

The RET NSCLC Test is a specialized diagnostic procedure aimed at detecting rearrangements in the RET gene, which are implicated in the development of non-small cell lung cancer (NSCLC). This test is crucial for patients diagnosed with NSCLC as it helps in identifying whether they are candidates for targeted therapy that specifically addresses RET gene mutations. Conducted at DNA Labs UAE, a leading facility in genetic testing, this test offers precise and reliable results. The cost of the RET NSCLC Test is 1800 AED, reflecting the sophisticated technology and expertise involved in conducting this advanced molecular diagnostic test. By identifying the genetic alterations in the RET gene, healthcare providers can tailor treatment plans to improve outcomes and quality of life for NSCLC patients.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

RET NSCLC Test Cost AED: 1800.0 – Symptoms, Diagnosis, and More

Are you concerned about non-small cell lung cancer (NSCLC)? At DNA Labs UAE, we offer the RET NSCLC Test to help diagnose and treat this condition. Read on to learn more about the test details, cost, symptoms, diagnosis, and more.

Test Name: RET NSCLC Test

Components:

  • Paraffin embedded tissue blocks

Price:

1800.0 AED

Sample Condition:

Tumor tissue

Report Delivery:

7-8 days

Method:

FISH (Fluorescence In Situ Hybridization)

Test Type:

Genetics

Doctor:

Oncology

Test Department:

Genetic Testing

Pre Test Information:

RET (NSCLC) test can be done with a doctor’s prescription. Please note that the prescription is not applicable for surgery and pregnancy cases or individuals planning to travel abroad.

Test Details:

The RET (rearranged during transfection) gene is responsible for encoding a receptor tyrosine kinase. It is primarily associated with the development of non-small cell lung cancer (NSCLC), specifically a subset known as RET fusion-positive NSCLC. In RET fusion-positive NSCLC, the RET gene fuses with other genes, resulting in the production of abnormal RET fusion proteins. These fusion proteins have constitutive kinase activity, leading to uncontrolled cell growth and proliferation.

While RET fusion-positive NSCLC accounts for a small percentage of all NSCLC cases, it has been identified as a target for therapy. Promising results have been observed in clinical trials using RET inhibitors, such as selpercatinib and pralsetinib, for the treatment of RET fusion-positive NSCLC. Genetic testing is usually conducted to identify patients with this specific type of NSCLC, as targeted therapy with RET inhibitors has shown improved outcomes for these patients.

If you are experiencing symptoms of NSCLC or have been diagnosed with NSCLC, the RET NSCLC Test can provide valuable information for your treatment plan. Book your appointment with DNA Labs UAE today and take a step towards better health.

Test Name RET NSCLC Test
Components Paraffin embedded tissue blocks
Price 1800.0 AED
Sample Condition Tumor tissue
Report Delivery 7-8 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information RET (NSCLC) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

RET (rearranged during transfection) is a gene that encodes a receptor tyrosine kinase. It is primarily associated with the development of non-small cell lung cancer (NSCLC), specifically a subset of NSCLC known as RET fusion-positive NSCLC.

In RET fusion-positive NSCLC, the RET gene fuses with other genes, resulting in the production of abnormal RET fusion proteins. These fusion proteins have constitutive kinase activity, leading to uncontrolled cell growth and proliferation.

RET fusion-positive NSCLC accounts for a small percentage of all NSCLC cases, but it has been identified as a target for therapy. Several RET inhibitors have been developed and approved by the FDA for the treatment of RET fusion-positive NSCLC, including selpercatinib and pralsetinib.

Genetic testing is usually conducted to identify patients with RET fusion-positive NSCLC, as targeted therapy with RET inhibitors has shown promising results in clinical trials, leading to improved outcomes for these patients.

SKU: TEST-5005